Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase II study of neoadjuvant chemotherapy with L-OHP and S-1 for locally advanced colorectal cancer with lymph node metastases

ABSTRACT: Interventions: S-1 80mg/m2/day for 14 days plus L-OHP 100mg/m2 on day 1 every 21 days is administered for 3 course. After treatment, response rate is evaluated. Surgical operation is performed. Primary outcome(s): Response rate Study Design: Single arm Non-randomized

DISEASE(S): Locally Advanced Colorectal Cancer With Lymph Node Metastases

PROVIDER: 2618988 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II study of neoadjuvant chemotherapy with CPT-11 and S-1 for locally advanced colorectal cancer with lymph node metastases.

Project description:Interventions: S-1 80mg/m2/day for 14 days plus CPT-11 100mg/m2 on day 1 and 15 every 28 days is administered for 2 course. After treatment, response rate is evaluated. Surgical operation is performed. Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2617187 | ecrin-mdr-crc

Evaluation of the efficacy of XELOX(L-OHP: 100mg/m2)+Bevacizumab for patient with metastatic or recurrent Colorectal Cancer as first-line chemotherapy

Project description:Interventions: Capecitabine plus oxaliplatin(L-OHP: 100mg/m2) with bevacizumab Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

| 2623078 | ecrin-mdr-crc

Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal cancer

Project description:Interventions: Irinotecan plus S-1 with cetuximab combination therapy Cetuximab 400mg/m2 day1 and then 250mg/m2 day 8,15,22 weekly until PD, or Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD S-1 S-1 80mg [BSA<1.25m2] or 100mg [1.25m2<BSA<1.5m2] or 120mg [1.5m2<BSA]/body/day, day 1-14, q4weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2620325 | ecrin-mdr-crc

Phase II study of S-1 plus irinotecan combined with biweekly cetuximab as 2nd-line chemotherapy in patients with wild type KRAS unresectable colorectal cancer, who had previously received oxaliplatin-based chemoterapy without CV port. (FUTURE 1103 STUDY)

Project description:Interventions: Irinotecan plus S-1 (IRSI) with biweekly cetuximab combination therapy 1)Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD 2)S-1 80mg [BSA<1.25m2] or 100mg [1.25m2<BSA<1.5m2] or 120mg [1.5m2<BSA]/body/day, day 1-14, q4weeks 3)Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2622245 | ecrin-mdr-crc

Phase II study of resection of primary colorectal caner and synchronous liver metastasis after S-1 + oxaliplatin (SOX) + Bevacizumab(Bmab) therapy and adjuvant S-1 chemotherapy

Project description:Interventions: S-1 is administered orally at 80mg/m2/day for 14 consecuitive days followed by a 7 day rest. L-OHP is given intravenously on days 1, at a dose of 130mg/m2/day.Bevacizumab is given intravenously on days 1, at a dose of 7.5mg/kg/day. 21 days are assumed 1 course, and chemotherapy consisted of 4 courses. Surgery is carried out in 8 to 12 weeks after the end of chemotherapy. Primary outcome(s): progression free survival Study Design: Single arm Non-randomized

| 2647236 | ecrin-mdr-crc

Study of resection of primary colorectal caner and synchronous liver metastasis after SOX + Bmab

| 2613833 | ecrin-mdr-crc

Phase II trial of S-1+oxaliplatin+Cetuximab as first-line treatment in patients with kras-wild type unresectable advanced colorectal cancer - KODK 9 -

Project description:Interventions: (SOX+Cmab) L-OHP 85mg/m2 i.v.(day1) Cmab 500mg/m2 i.v.(day1) S-1 80mg/m2(day1-7) to be repeated every 2 weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2624365 | ecrin-mdr-crc

Ribo-seq of human colorectal cancer cell line HCT116/L-OHP against HCT116

Project description:Oxaliplatin (L-OHP) serves as a standard chemotherapy for colorectal cancer, while the drug resistance is still a considerable challenge. Dysregulation of lncRNA is involved in cancer and recent translatomics has found some alleged lncRNA actually contained small open reading frames and could encode short peptides. This ribosome footprint profiling (Ribo-seq) was a paired-end sequencing and aimed to investigate whether lncRNA could regulate oxaliplatin resistance in colorectal cancer by encoding short peptides.

2021-11-12 | E-MTAB-10805 | biostudies-arrayexpress

RNA-seq of human colorectal cancer cell line HCT116/L-OHP against HCT116

Project description:Oxaliplatin (L-OHP) serves as a standard chemotherapy for colorectal cancer, while the drug resistance is still a considerable challenge. A number of previously unknown transcripts have been identified in recent years, the vast majority of which are considered long non-coding RNA (lncRNA). Dysregulation of the lncRNA is involved in the genesis and progression of cancer. This RNA-seq was a paired-end sequencing and aimed to investigate the expression profile of lncRNA associated with oxaliplatin resistance in colorectal cancer.

2021-11-12 | E-MTAB-10806 | biostudies-arrayexpress

A randomized Phase II study comparing SOX+B-mab with SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with KRAS wild type.

Project description:Interventions: A group (SOX+B-mab) TS-1 administered for 14 days followed by 7 days rest according to body surface area. L-OHP is administered intravenously in 130 mg/m2 at day 1. B-mab is administered intravenously in 7.5 mg/kg by tri-weekly. B group (SOX+C-mab) TS-1 administered for 14 days followed by 7 days rest according to body surface area. L-OHP is administered intravenously in 130 mg/m2 at day 1. C-mab is administered intravenously in 400 mg/m2 on day 1, then 250 mg/m2 weekly thereafter. Or C-mab is administered intravenously in 500 mg/m2 by bi-weekly. Primary outcome(s): Response rate Study Design: Parallel Randomized

| 2622133 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data